Galapagos
Galapagos announces leadership changes amid planned company split
April 22, 2025Analytical & Laboratory Services, Research and Development CEO Appointment, Corporate, Galapagos, cell therapy
Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
January 4, 2024Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
Gilead invests $5.1 billion into Galapagos NV
July 15, 2019Sales and Marketing Galapagos, Gilead, biotech, collaboration, deal, drug discovery, pharma
Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV. The collaboration will see Gilead invest $5.1 …
Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal
September 7, 2018Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma
Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …
AbbVie and Galapagos extend deal
May 21, 2013Sales and Marketing AbbVie, Crohn's, Galapagos
AbbVie and Belgian biotech Galapagos have bolted on a development programme for Crohn’s disease to the selective JAK1 inhibitor they …
Roche bins Galapagos tie-up
March 12, 2013Sales and Marketing COPD, Galapagos, Roche
Roche has ended its three-year old alliance with Belgian drug discovery specialist Galapagos because of a ‘strategic change’. The companies …
Abbott buys into Galapagos’ RA candidate
February 29, 2012Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF
Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …
Contract research news in brief
September 20, 2010Research and Development Covance, Galapagos, MediData Solutions, MediSync BioServices, PPD, Quotient Bioresearch, i3
A round-up of recent news from the CRO sector, featuring updates from Covance, Quotient Bioresearch, PPD, i3, Galapagos, MediSync BioServices …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
